MRUS News and Press, Merus N.V. From 05/24/24

2024-05-24 12:58:09 ET More on BioAtla, HOOKIPA Pharma, etc. BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript AEye, Inc. (LIDR) Q1 2024 Earnings Call Transcript BioAtla: A Buried ADC Concern Gets Some New Life In 2024 AEye Q1 2024 Earnings Preview ...

2024-05-24 12:00:05 ET Asthika Goonewardene from Truist Financial issued a price target of $69.00 for MRUS on 2024-05-24 10:19:00. The adjusted price target was set to $69.00. At the time of the announcement, MRUS was trading at $60.99. The overall price target consensus...

Merus N.V. (NASDAQ: MRUS) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 38.42% on the day to $61. Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody th...

A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 5.3% to $0.0839 on volume of 148,968,464 shares Netcapital Inc. (NCPL) rose 66.0% to $0.2901 on volume of 111,713,040 shares Cue Health Inc. (HLTH) rose 33.6% to $0.126 on volume of 99,7...

2024-05-24 09:36:39 ET More on Merus Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement Merus gets FDA breakthrough therapy status for petosemtamab FDA accepts Merus application for Zeno for lung, pancreatic cancer Seeking Alpha’s...

-   60% response rate observed among 10 evaluable patients -   F avorable safety profile in 26 patients enrolled as of the abstract cutoff date , with no significant overlapping toxicities observed -   Conference call on Tuesday,...

MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster presentation : June 3, 2024, 1:30-4:30 p.m. CT UTRECHT, The Netherlands and CAMB...

2024-05-22 17:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-13 12:47:21 ET More on Merus Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement FDA accepts Merus application for Zeno for lung, pancreatic cancer Gilead to invest in Merus as part of a research deal Seeking Alpha’s Quant ...

Petosemtamab granted BTD for the treatment of previously treated HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics &...